These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 9703780

  • 1. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M.
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
    Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M.
    Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
    [Abstract] [Full Text] [Related]

  • 3. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M.
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
    Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Jänicke F, Graeff H.
    Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group.
    J Natl Cancer Inst; 2001 Jun 20; 93(12):913-20. PubMed ID: 11416112
    [Abstract] [Full Text] [Related]

  • 11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 12. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N, Kates RE, Schmitt M.
    J Clin Oncol; 2002 Feb 15; 20(4):1000-7. PubMed ID: 11844823
    [Abstract] [Full Text] [Related]

  • 13. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.
    Breast Cancer Res Treat; 1993 Feb 15; 24(3):195-208. PubMed ID: 8435475
    [Abstract] [Full Text] [Related]

  • 14. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 15. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, Nikolić-Vukosavljević D.
    Tumour Biol; 2015 Sep 15; 36(10):8193-200. PubMed ID: 25994573
    [Abstract] [Full Text] [Related]

  • 16. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
    Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N.
    Breast Cancer Res Treat; 1997 Apr 01; 43(2):153-63. PubMed ID: 9131271
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H, Schmitt M.
    Anticancer Res; 1998 Apr 01; 18(3C):2187-97. PubMed ID: 9703782
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 01; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 20. The role of cysteine and serine proteases in colorectal carcinoma.
    Herszènyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F.
    Cancer; 1999 Oct 01; 86(7):1135-42. PubMed ID: 10506696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.